Nasotestt
Phase 3Small molecule
Nasotestt is one of 35 small molecule programs targeting Hypogonadism. It is currently in Phase 3.
1
Indications
1
Total Trials
0
Active Trials
34
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
48 competitors in Hypogonadism
#DrugCompanyPhaseTrials
1Victoza
Novo NordiskApproved
Estrace
Novo NordiskApproved
Andriol
AAuxilium
Approved
Jatenzo
GGrupo Espanol de Tumores Neuroendocrinos
Approved
Delatestryl
AAntares Pharma Inc.
Approved
Arimidex
IIstituto Clinico Humanitas
Approved
Trelstar
OOncoVerity, Inc.
Approved
Avodart
Akero TherapeuticsApproved
Orgovyx
Sumitomo Pharma America, Inc.Approved
Nizoral
WWim Janssens
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Nasotestt. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- FFBM Industria Brasileira Ltda